

Francesco Caso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6667831/publications.pdf>

Version: 2024-02-01

186
papers

4,857
citations

101543

36
h-index

138484

58
g-index

192
all docs

192
docs citations

192
times ranked

4889
citing authors

#	ARTICLE	IF	CITATIONS
1	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. Autoimmunity Reviews, 2020, 19, 102524.	5.8	231
2	Overlap connective tissue disease syndromes. Autoimmunity Reviews, 2013, 12, 363-373.	5.8	150
3	Blau syndrome, clinical and genetic aspects. Autoimmunity Reviews, 2012, 12, 44-51.	5.8	126
4	Anakinra treatment in drug-resistant Behcetâ€™s disease: a case series. Clinical Rheumatology, 2015, 34, 1293-1301.	2.2	114
5	Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open, 2015, 1, e000097.	3.8	103
6	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	5.8	101
7	Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clinical Rheumatology, 2012, 31, 711-715.	2.2	100
8	Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology, 2014, 33, 833-839.	2.2	98
9	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmunity Reviews, 2014, 13, 1220-1229.	5.8	86
10	Adult-onset Stillâ€™s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	2.2	83
11	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmunity Reviews, 2015, 14, 1-9.	5.8	79
12	Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clinical Rheumatology, 2010, 29, 399-403.	2.2	77
13	Diagnosis and classification of relapsing polychondritis. Journal of Autoimmunity, 2014, 48-49, 53-59.	6.5	77
14	Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series. Dermatology, 2014, 228, 211-214.	2.1	74
15	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	3.4	71
16	Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunologic Research, 2015, 61, 147-153.	2.9	70
17	Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs in R and D, 2017, 17, 509-522.	2.2	69
18	Biological Treatments in Behçetâ€™s Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation, 2014, 2014, 1-14.	3.0	68

#	ARTICLE	IF	CITATIONS
19	Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-15.	1.6	67
20	JAK/STAT/PKC γ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. <i>Immunologic Research</i> , 2014, 58, 61-69.	2.9	65
21	Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. <i>Mediators of Inflammation</i> , 2013, 2013, 1-16.	3.0	64
22	Long-term safety of anti-TNF- α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. <i>Clinical Rheumatology</i> , 2014, 33, 273-276.	2.2	64
23	Psoriatic arthritis and psoriasis: differential diagnosis. <i>Clinical Rheumatology</i> , 2016, 35, 1893-1901.	2.2	64
24	Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , 2014, 33, 1197-1207.	2.2	58
25	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. <i>Autoimmunity Reviews</i> , 2015, 14, 90-97.	5.8	55
26	Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms. <i>Autoimmunity Reviews</i> , 2020, 19, 102572.	5.8	50
27	Drug Retention Rates and Treatment Discontinuation among Anti-TNF- α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	3.0	49
28	Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. <i>Autoimmunity Reviews</i> , 2019, 18, 565-575.	5.8	49
29	Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. <i>Frontiers in Immunology</i> , 2018, 9, 2363.	4.8	46
30	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF- κ B pathway. <i>Arthritis Research and Therapy</i> , 2015, 17, 93.	3.5	43
31	Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. <i>Clinical Rheumatology</i> , 2018, 37, 579-586.	2.2	43
32	Simple clinical indicators for early psoriatic arthritis detection. <i>SpringerPlus</i> , 2014, 3, 759.	1.2	42
33	Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules". <i>Clinical Rheumatology</i> , 2018, 37, 1739-1741.	2.2	42
34	IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation. <i>Pharmacological Research</i> , 2019, 147, 104351.	7.1	41
35	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	3.5	40
36	Small molecule therapy for managing moderate to severe psoriatic arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1557-1567.	1.8	39

#	ARTICLE	IF	CITATIONS
37	From autoinflammation to autoimmunity: old and recent findings. <i>Clinical Rheumatology</i> , 2018, 37, 2305-2321.	2.2	39
38	Interaction between microbiome and host genetics in psoriatic arthritis. <i>Autoimmunity Reviews</i> , 2018, 17, 276-283.	5.8	38
39	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity? characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	3.5	38
40	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	5.8	38
41	Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. <i>Immunologic Research</i> , 2013, 56, 390-397.	2.9	37
42	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , 2015, 34, 17-28.	2.2	37
43	Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvasculature in the joints of psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1903-1912.	2.2	36
44	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1571-1580.	2.2	36
45	Emerging drugs for psoriatic arthritis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 69-79.	2.4	36
46	Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. <i>Clinical Rheumatology</i> , 2018, 37, 397-405.	2.2	36
47	New Developments in Magnetic Resonance Imaging of the Nail Unit. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 49-53.	2.2	35
48	Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study. <i>Journal of Rheumatology</i> , 2016, 43, 2149-2154.	2.0	35
49	The use of TNF- β blockers in psoriatic arthritis patients with latent tuberculosis infection. <i>Clinical Rheumatology</i> , 2014, 33, 543-547.	2.2	34
50	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. <i>Rheumatology International</i> , 2020, 40, 951-958.	3.0	34
51	Magnetic Resonance Imaging of Nail Unit in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 42-45.	2.2	33
52	Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. <i>Joint Bone Spine</i> , 2014, 81, 190-192.	1.6	31
53	Current evidence in the field of the management with TNF- β inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 641-650.	3.1	31
54	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1050-1051.	1.9	31

#	ARTICLE	IF	CITATIONS
55	Psoriatic Disease 10 Years Later. Journal of Rheumatology, 2017, 44, 1298-1301.	2.0	31
56	An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Review of Clinical Immunology, 2019, 15, 823-836.	3.0	31
57	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS ONE, 2020, 15, e0235326.	2.5	31
58	Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clinical Rheumatology, 2014, 33, 1355-1357.	2.2	30
59	The Definition and Measurement of Axial Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 40-42.	2.2	30
60	Progress in understanding and utilizing TNF- α inhibition for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 315-331.	3.0	30
61	Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomedicine and Pharmacotherapy, 2021, 142, 111980.	5.6	30
62	Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clinical Rheumatology, 2015, 34, 1817-1820.	2.2	29
63	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
64	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	2.2	28
65	Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE, 2018, 13, e0205506.	2.5	28
66	Untangling the Web of Systemic Autoinflammatory Diseases. Mediators of Inflammation, 2014, 2014, 1-15.	3.0	25
67	Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. Reviews on Recent Clinical Trials, 2018, 13, 199-209.	0.8	25
68	Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217251.	0.9	25
69	Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2021, 80, e46-e46.	0.9	25
70	Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opinion on Pharmacotherapy, 2013, 14, 2311-2313.	1.8	24
71	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	3.0	24
72	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. Rheumatology, 2021, 60, 4844-4849.	1.9	23

#	ARTICLE	IF	CITATIONS
73	Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2023-2029.	2.2	22
74	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 103-108.	1.9	22
75	Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1-2.	3.1	21
76	Bilateral dexamethasone intravitreal implant in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis. <i>Clinical Rheumatology</i> , 2015, 34, 1145-1148.	2.2	21
77	Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. <i>Clinical Rheumatology</i> , 2017, 36, 391-399.	2.2	21
78	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "without psoriasis". <i>Clinical Rheumatology</i> , 2019, 38, 2547-2552.	2.2	21
79	Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration. <i>Clinical Rheumatology</i> , 2019, 38, 903-911.	2.2	21
80	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. <i>Rheumatology and Therapy</i> , 2020, 7, 867-882.	2.3	21
81	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 409-420.	3.0	21
82	Working the endless puzzle of hereditary autoinflammatory disorders. <i>Modern Rheumatology</i> , 2014, 24, 381-389.	1.8	20
83	Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 328-338.	2.5	20
84	Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 757-766.	5.0	20
85	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	3.0	20
86	Role of thymopoiesis and inflamm-aging in COVID-19 phenotype. <i>Pediatrics and Neonatology</i> , 2020, 61, 364-365.	0.9	20
87	IL-17A-induced inflammation modulates the mPGC-1/PPAR β pathway in monocytes/macrophages. <i>British Journal of Pharmacology</i> , 2022, 179, 1857-1873.	5.4	20
88	Weekly oral alendronate in mevalonate kinase deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 196.	2.7	19
89	Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis. <i>Clinical Rheumatology</i> , 2020, 39, 1157-1165.	2.2	19
90	The enthesopathy of celiac patients: effects of gluten-free diet. <i>Clinical Rheumatology</i> , 2014, 33, 537-541.	2.2	18

#	ARTICLE	IF	CITATIONS
91	Ultrasonographic Evidence of Predominance of Acute Extracapsular and Chronic Intrasynovial Patterns in 100 Cases of Psoriatic Hand Dactylitis. <i>Journal of Rheumatology</i> , 2020, 47, 227-233.	2.0	18
92	Enteropathic spondyloarthritis: Results from a large nationwide database analysis. <i>Autoimmunity Reviews</i> , 2020, 19, 102457.	5.8	18
93	Efficacy of anakinra in refractory Behçet's disease sacroiliitis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S171.	0.8	18
94	<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 53-75.	3.2	17
95	Retention rates and identification of factors associated with anti-TNF±, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. <i>Clinical Rheumatology</i> , 2020, 39, 2663-2670.	2.2	17
96	Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 137-140.	0.8	17
97	A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1767-1769.	1.9	16
98	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Stillâ€™s disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	1.9	16
99	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016, 68, 126-136.	0.9	15
100	Impact of 24Âmonths of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. <i>Clinical Rheumatology</i> , 2016, 35, 1615-1618.	2.2	15
101	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. <i>Drugs and Aging</i> , 2019, 36, 909-925.	2.7	15
102	Pathogenesis of Psoriatic Arthritis. <i>Critical Reviews in Immunology</i> , 2019, 39, 361-377.	0.5	15
103	Serum amyloid-A in Behçetâ€™s disease. <i>Clinical Rheumatology</i> , 2014, 33, 1165-1167.	2.2	14
104	Psoriatic Disease: Clinical Staging. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 24-26.	2.2	14
105	Rheumatic Complaints in Women Taking Aromatase Inhibitors for Treatment of Hormone-Dependent Breast Cancer. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 169-172.	0.9	13
106	The occurrence of lower limb enthesopathy in coeliac disease patients without clinical signs of articular involvement. <i>Rheumatology</i> , 2013, 52, 893-897.	1.9	13
107	Tackling the autoimmune side in Spondyloarthritis: A systematic review. <i>Autoimmunity Reviews</i> , 2020, 19, 102648.	5.8	13
108	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. <i>Journal of Translational Medicine</i> , 2020, 18, 489.	4.4	13

#	ARTICLE	IF	CITATIONS
109	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	3.4	13
110	Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. <i>Clinical Rheumatology</i> , 2017, 36, 1589-1593.	2.2	12
111	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1497.	3.5	12
112	A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation. <i>Journal of Clinical Medicine</i> , 2020, 9, 719.	2.4	12
113	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
114	Early Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 26-27.	2.2	11
115	Fragility Fractures in Patients with Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 36-39.	2.2	11
116	Interleukin-1 blockade in neurodegenerative disease: a case-based reflection. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1046-1049.	1.9	11
117	Which composite measures to use in psoriatic arthritis?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 125-126.	8.0	11
118	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262.	2.0	10
119	<p><Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 143-156.	1.6	10
120	Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 971-976.	2.2	10
121	Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. <i>Clinical Rheumatology</i> , 2020, 39, 3383-3392.	2.2	10
122	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. <i>Clinical Rheumatology</i> , 2021, 40, 2251-2262.	2.2	10
123	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	3.3	10
124	CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S71-5.	0.8	10
125	Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF- α therapy. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 507-12.	0.8	10
126	Calibration of an automated California mastitis test with focus on the device-dependent variation. <i>SpringerPlus</i> , 2014, 3, 760.	1.2	9

#	ARTICLE	IF	CITATIONS
127	Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis. <i>Medicine (United States)</i> , 2015, 94, e1170.	1.0	9
128	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 79-81.	2.2	9
129	Elderly psoriatic arthritis patients on TNF- α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. <i>Clinical Rheumatology</i> , 2017, 36, 1797-1802.	2.2	8
130	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 785-796.	1.8	8
131	Dactylitis in enteropathic spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 842-847.	0.8	8
132	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	7
133	Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. <i>Advances in Rheumatology</i> , 2021, 61, 45.	1.7	7
134	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. <i>Scientific Reports</i> , 2022, 12, 7498.	3.3	7
135	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
136	Blau syndrome and latent tubercular infection: an unresolved partnership. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 586-587.	1.9	6
137	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1498-1501.	0.9	6
138	Musculoskeletal Ultrasound in Monitoring Clinical Response to Treatment in Acute Symptomatic Psoriatic Dactylitis: Results from a Multicentre Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3127.	2.4	6
139	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	2.2	6
140	The role of the F402L allele in the NLRP12-autoinflammatory disorder. Reply to: F402L variant in NLRP12 in subjects with undiagnosed periodic fevers and in healthy controls, De Pieri et al. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 994.	0.8	6
141	Mud-bath therapy and oral glucosamine sulfate in patients with knee osteoarthritis: a randomized, controlled, crossover study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 618-24.	0.8	6
142	The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 495-496.	1.9	5
143	Alopecia areata in a patient with psoriatic arthritis and Crohn's disease receiving etanercept. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 219-220.	1.9	5
144	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 473-475.	1.9	5

#	ARTICLE	IF	CITATIONS
145	Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatologic and rheumatologic patients already under treatment. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e77-e79.	1.2	5
146	Sensitivity to change and clinical correlations of the novel DACTylitis gLObal Sonographic (DACTOS) score in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 4103-4111.	1.9	5
147	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	5
148	Response to: "Can telemedicine improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?" by Akpabio et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e143-e143.	0.9	4
149	Coeliac disease is a risk factor for the development of seronegative arthritis in patients with autoimmune thyroid disease. <i>Rheumatology</i> , 2021, 60, 2440-2447.	1.9	4
150	Thalassemic Trait Prevalence in Patients Affected by Psoriatic Arthritis in Anti-TNF Treatment. <i>Drug Development Research</i> , 2014, 75, S20-S22.	2.9	3
151	Cardiovascular Involvement in Psoriatic Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 409-426.	0.1	3
152	Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. <i>Clinical Rheumatology</i> , 2021, , 1.	2.2	3
153	Ultrasound Effectiveness of Steroid Injection for hand Psoriatic Dactylitis: Results from a Longitudinal Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1809-1826.	2.3	3
154	Association between Leeds Dactylitis Index and ultrasonographic features: a multicentre study on psoriatic hand dactylitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1112-1117.	0.8	3
155	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 127-131.	0.8	2
156	From Old to New Cardiovascular Complications in Ankylosing Spondylitis. <i>Israel Medical Association Journal</i> , 2017, 19, 506-509.	0.1	2
157	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.8	2
158	Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 961-969.	0.8	2
159	Scores versus clinical profiles in therapeutic decisions: a positive example from the Italian Medicines Agency (AIFA) decisions in the field of osteoporosis. <i>Clinical Rheumatology</i> , 2018, 37, 575-578.	2.2	1
160	TNF \pm -inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. <i>Clinical Pharmacist</i> , 2017, , .	0.0	1
161	Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. <i>Journal of Experimental Pharmacology</i> , 2020, 12, 487-502.	3.2	1
162	Section A2: Spondyloarthritis. <i>Clinical Drug Investigation</i> , 2013, 33, 95-112.	2.2	0

163	THU0395â€¦Adult Onset Still's Disease: A Multicenter Retrospective Cohort Study of 233 Italian Patients. Annals of the Rheumatic Diseases, 2014, 73, 318.2-318.	0.9	0
164	AB0579â€¦Behcet's Disease and Pregnancy. May Recurrent Fever Suggest A Disease Subset with Different Outcome?. Annals of the Rheumatic Diseases, 2014, 73, 997.2-997.	0.9	0
165	Efficacit� th�rapeutique du rituximab chez un jeune patient atteint d�une maladie syst�mique associ�e aux IgG4�avec scl�rite r�fractaire. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 264-265.	0.0	0
166	FRIO464â€¦Long-Term Efficacy of Ustekinumab Treatment in Patients Affected by Psoriatic Arthritis Previously Treated with TNF Inhibitors. Annals of the Rheumatic Diseases, 2016, 75, 605.2-606.	0.9	0
167	Conventional and Biological DMARDs in Systemic Rheumatic Diseases. Handbook of Systemic Autoimmune Diseases, 2018, 15, 161-182.	0.1	0
168	AB0761â€¦SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN REAL LIFE: AN ITALIAN EXPERIENCE. , 2019, , .		0
169	OP0090â€¦THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVATIONAL, GIRRCs STUDY. , 2019, , .		0
170	Autoimmune screening before adenovirus vector-based DNA vaccine in women may avoid underuse for all the subjects. Neurological Sciences, 2021, 42, 5421-5423.	1.9	0
171	SAT0338â€¦Prediction of cardiovascular events in patients with psoriatic arthritis: performance of five risk algorithms in an italian bicentric study. , 2018, , .		0
172	Vasculitis and COVID-19: what do we have to know?. Italian Journal of Medicine, 2020, 14, 213-215.	0.3	0
173	The anti-drug antibodies detection: a valuable tool for clinical response loss in psoriatic patients?. Italian Journal of Dermatology and Venereology, 2020, , .	0.2	0
174	The antidrug antibodies detection: a valuable tool for clinical response loss in psoriatic patients?. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.2	0
175	Effects of tumor necrosis factor-� inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis. Clinical and Experimental Rheumatology, 2015, 33, 411-3.	0.8	0
176	Clinical effects of mud-bath therapy and oral glucosamine sulfate after 6 months of discontinuation in patients with knee osteoarthritis: results from a randomised, controlled, crossover study. Clinical and Experimental Rheumatology, 2017, 35, 169.	0.8	0
177	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
178	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard. Clinical and Experimental Rheumatology, 0, , .	0.8	0
179	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 0, , .	0.8	0
180	COVID-19 clinical spectrum in psoriatic arthritis patients on biologics and tsDMARDs: results from a cohort at an Italian epicentre of the pandemic's third wave. Clinical and Experimental Rheumatology, 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
181	Title is missing!., 2020, 15, e0235326.		0
182	Title is missing!., 2020, 15, e0235326.		0
183	Title is missing!., 2020, 15, e0235326.		0
184	Title is missing!., 2020, 15, e0235326.		0
185	COVID-19 clinical spectrum in psoriatic arthritis patients on biologics and tsDMARDs: results from a cohort at an Italian epicentre of the pandemic's third wave.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
186	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0